Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007